📊 JAGX Key Takeaways
Is Jaguar Health, Inc. (JAGX) a Good Investment?
Jaguar Health exhibits critical financial distress with negative stockholders equity of -$15.8M (technical insolvency) and severe liquidity constraints (current ratio 0.50x). Despite positive operating cash flow, the combination of declining revenue, net losses of $7.0M, and negative net margins of -34.6% indicates an unsustainable trajectory without major capital injection or business restructuring.
Jaguar Health shows modest top-line growth, but the quality of that growth is weak given extremely negative operating and net margins and deeply negative free cash flow. The balance sheet is fragile, with low liquidity, high leverage relative to a very small equity base, and continued losses that suggest ongoing dependence on external financing rather than internally generated cash.
Why Buy Jaguar Health, Inc. Stock? JAGX Key Strengths
- Positive operating cash flow of $8.8M provides near-term operational runway
- Strong interest coverage ratio of 14.6x demonstrates debt service capability
- Operating margin of 50.2% suggests potential profitability in core operations if revenue stabilizes
- Revenue grew 19.8% year over year, indicating some commercial demand expansion
- Asset base still exceeds liabilities, leaving the company with positive stockholders' equity
- Capital expenditure requirements appear low, which limits cash drain from fixed investment
JAGX Stock Risks: Jaguar Health, Inc. Investment Risks
- Negative stockholders equity of -$15.8M indicates technical insolvency and balance sheet insolvency
- Critically deficient liquidity ratios (current 0.50x, quick 0.30x) with liabilities exceeding assets by $15.8M
- Declining revenue (-1.5% YoY) combined with $7.0M net losses creates unsustainable cash burn trajectory
- Pharmaceutical sector requires sustained R&D investment and cash reserves for pipeline sustainability
- Operating losses are extremely large relative to revenue, with a -298.0% operating margin
- Liquidity is tight, with a 0.81x current ratio, 0.52x quick ratio, and only $3.53M in cash
- Free cash flow and operating cash flow are heavily negative, increasing refinancing and dilution risk
Key Metrics to Watch
- Stockholders equity recovery to positive territory - critical going-concern threshold
- Quarterly revenue trend and gross margin recovery
- Cash runway and monthly cash burn rate relative to operating cash flow
- Quarterly operating cash burn relative to cash balance
- Revenue growth versus operating loss trend
Jaguar Health, Inc. (JAGX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 43.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
JAGX Profit Margin, ROE & Profitability Analysis
JAGX vs Healthcare Sector: How Jaguar Health, Inc. Compares
How Jaguar Health, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Jaguar Health, Inc. Stock Overvalued? JAGX Valuation Analysis 2026
Based on fundamental analysis, Jaguar Health, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Jaguar Health, Inc. Balance Sheet: JAGX Debt, Cash & Liquidity
JAGX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Jaguar Health, Inc.'s revenue has grown significantly by 102% over the 5-year period, indicating strong business expansion. The most recent EPS of $-130.69 indicates the company is currently unprofitable.
JAGX Revenue Growth, EPS Growth & YoY Performance
JAGX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.2M | N/A | $-13.60 |
| Q3 2025 | $3.1M | -$9.5M | $-6.28 |
| Q2 2025 | $2.7M | -$9.5M | $-2.66 |
| Q1 2025 | $2.2M | -$9.2M | $-16.70 |
| Q3 2024 | $2.8M | -$7.8M | $-1.05 |
| Q3 2020 | $973.0K | -$7.6M | N/A |
| Q2 2020 | $1.7M | -$9.2M | N/A |
| Q1 2020 | $869.0K | -$7.9M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Jaguar Health, Inc. Dividends, Buybacks & Capital Allocation
JAGX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Jaguar Health, Inc. (CIK: 0001585608)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JAGX
What is the AI rating for JAGX?
Jaguar Health, Inc. (JAGX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are JAGX's key strengths?
Claude: Positive operating cash flow of $8.8M provides near-term operational runway. Strong interest coverage ratio of 14.6x demonstrates debt service capability. ChatGPT: Revenue grew 19.8% year over year, indicating some commercial demand expansion. Asset base still exceeds liabilities, leaving the company with positive stockholders' equity.
What are the risks of investing in JAGX?
Claude: Negative stockholders equity of -$15.8M indicates technical insolvency and balance sheet insolvency. Critically deficient liquidity ratios (current 0.50x, quick 0.30x) with liabilities exceeding assets by $15.8M. ChatGPT: Operating losses are extremely large relative to revenue, with a -298.0% operating margin. Liquidity is tight, with a 0.81x current ratio, 0.52x quick ratio, and only $3.53M in cash.
What is JAGX's revenue and growth?
Jaguar Health, Inc. reported revenue of $20.3M.
Does JAGX pay dividends?
Jaguar Health, Inc. does not currently pay dividends.
Where can I find JAGX SEC filings?
Official SEC filings for Jaguar Health, Inc. (CIK: 0001585608) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JAGX's EPS?
Jaguar Health, Inc. has a diluted EPS of $-13.60.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JAGX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Jaguar Health, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JAGX stock overvalued or undervalued?
Valuation metrics for JAGX: ROE of N/A (sector avg: 15%), net margin of -34.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JAGX stock in 2026?
Our dual AI analysis gives Jaguar Health, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is JAGX's free cash flow?
Jaguar Health, Inc.'s operating cash flow is $8.8M, with capital expenditures of $16.0K. FCF margin is 43.5%.
How does JAGX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -34.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.50 (avg: 2).